The Paclitaxel (TAXUS™)-Eluting Stent

A Review of its Use in the Management of de novo Coronary Artery Lesions

  • Waugh, John
  • Wagstaff, Antona J

  • Adis International Inc., Yardley, Pennsylvania, USA

Various sections of the manuscript reviewed by:V. Bhatia, Department of Internal Medicine, SUNY, Buffalo, New York, USA; L. Büllesfeld, Abt fur Kardiologie/Angiologie, Krankenhaus and Herzzentrum Siegburg, Siegburg, Germany; A. Colombo, Ospedale San Raffaele, Milano, Italy; G.F. Guagliumi, Cardiovascular Department, Ospedali Riuniti, Bergamo, Italy; S.T. Laroia, Department of Internal Medicine, University of North Dakota School of Medicine and Health Sciences, Fargo, North Dakota, USA; H.C. Lowe, Cardiology Department, Concord Repatriation General Hospital, Sydney, New South Wales, Australia; G. Musumeci, Cardiovascular Department, Ospedali Riuniti, Bergamo, Italy; A. Raizner, The Methodist DeBakey Heart Center, Baylor College of Medicine, Houston, Texas, USA.

Correspondence: John Waugh, Adis International Inc., 770 Township Line Road, Suite 300, Yardley, PA 19067, USA. E-mail: [email protected]

American Journal of Cardiovascular Drugs 4(4):p 257-268, 2004.

The TAXUS™/Express2™ stent contains paclitaxel 1 µg/mm2. On deployment, paclitaxel is slowly released into the intimal tissue of the coronary artery to prevent cell proliferation and neointimal hyperplasia. When deployed in patients with previously untreated coronary artery lesions, the paclitaxel-eluting stent (PES) effectively reduces the need for revascularization without increasing the risk of in-stent thrombosis. While long-term outcomes data and comparative efficacy and cost-benefit trials versus other drug-eluting stents are required, the PES appears to be an attractive alternative for the management of de novo coronary artery lesions.

Copyright © 2004 Adis Data Information BV
View full text|Download PDF